The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis

Abstract Background Brain metastases (BM) are common complications of metastatic cancer and typically occur in patients with melanoma. This study aims to investigate the dabrafenib plus trametinib for patients diagnosed with melanoma brain metastasis (MBM). Method This review adhered to the Preferre...

Descripció completa

Dades bibliogràfiques

Autors principals:	Mohammad Amin Habibi, Mohammad Sina Mirjani, Bardia Hajikarimloo, Mohsen Dashti, Afsaneh Ghasemzadeh, Seyed Hesam Hojjat, Mohammad Shahir Eftekhar, Kosar Doraghi, Yalda Ghazizadeh, Fateme Aghaei, Shaghayegh Karami, Mehrshad Edalat, Farhang Rashidi, Sajjad Ahmadpour, Sina Ahmadi
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2025-06-01
Col·lecció:	Discover Oncology
Matèries:	BRAF inhibitor Dabrafenib MEK inhibitor Melanoma Melanoma brain metastasis Trametinib
Accés en línia:	https://doi.org/10.1007/s12672-025-02778-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!